A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000

被引:137
作者
Stone, PW
Larson, E
Kawar, LN
机构
[1] Columbia Univ, Sch Nursing, New York, NY 10032 USA
[2] Univ Rochester, Sch Nursing, Rochester, NY 14627 USA
关键词
D O I
10.1067/mic.2002.121099
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. Nosocomial infections (NIs) are a serious patient safety issue. infection control personnel are responsible for implementing interventions to reduce this risk. The purpose of this systematic review was to audit the published economic evidence of the attributable cost of NIs and interventions conducted by infection control professionals and to evaluate the methods used. Economic evaluation methodology and recommendations for standardization are reviewed. Methods: A search of MEDLINE and HealthSTAR with medical subject headings or text words "nosocomial infections," "infection control," or "hospital acquired infections" cross-referenced with "costs," "cost analysis," "economics," or "cost-effectiveness analysis" was conducted. Published review articles were also searched. inclusion criteria included articles published between 1990 and 2000 that contained an abstract and original cost estimate and were written in English. Results were standardized into a common currency. Results. Fifty-five studies were eligible. Approximately one quarter examined NIs in intensive care patients (n=13). Most studies were conducted from the hospital perspective (n=48). The costs attributable to bloodstream (mean=$38,703) and methicillin-resistant Staphylococcus aureus infections (mean=$35,367) were the largest. Conclusions: Increased standardization and rigor are needed. Clinicians should partner with economists and policy analysts to expand and improve the economic evidence available to reduce hospital complications such as NI and other adverse patient/staff outcomes.
引用
收藏
页码:145 / 152
页数:8
相关论文
共 82 条
[1]   Nosocomial methicillin-resistant and methicillin-susceptible, Staphylococcus aureus primary bacteremia:: At what costs [J].
Abramson, MA ;
Sexton, DJ .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (06) :408-411
[2]  
ALTMAN LK, 1988, NY TIMES 0302, pA12
[3]  
[Anonymous], 2000, HLTH PEOPL 2010, V2nd
[4]   Control of transmission of vancomycin-resistant Enterococcus faecium in a long-term-care facility [J].
Armstrong-Evans, M ;
Litt, M ;
McArthur, MA ;
Willey, B ;
Cann, D ;
Liska, S ;
Nusinowitz, S ;
Gould, R ;
Blacklock, A ;
Low, DE ;
McGeer, A .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (05) :312-317
[5]  
Berglund B., 1995, ARCH CTR SENSORY RES, V2, P1
[6]  
*CAN COORD OFF HLT, 1997, GUID EC EV PHARM
[7]   COST IMPROVEMENTS THROUGH THE ESTABLISHMENT OF PRUDENT INFECTION CONTROL PRACTICES IN A BRAZILIAN GENERAL-HOSPITAL, 1986-1989 [J].
CAVALCANTE, MDA ;
BRAGA, OB ;
TEOFILO, CH ;
OLIVEIRA, EN ;
ALVES, A .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1991, 12 (11) :649-653
[8]  
*CDCP, 1992, MMWR-MORBID MORTAL W, V41, P783
[9]   Control of endemic methicillin-resistant Staphylococcus aureus -: A cost-benefit analysis in an intensive care unit [J].
Chaix, C ;
Durand-Zaleski, I ;
Alberti, C ;
Brun-Buisson, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (18) :1745-1751
[10]   A comprehensive league table of cost-utility ratios and a sub-table of "Panel-worthy" studies [J].
Chapman, RH ;
Stone, PW ;
Sandberg, EA ;
Bell, C ;
Neumann, PJ .
MEDICAL DECISION MAKING, 2000, 20 (04) :451-467